Add 2 More Reports For 20% off

Report Overview

The von Hippel-Lindau disease market is expected to grow at a CAGR of 7.97% during the forecast period of 2025-2034, driven by the increased research and clinical trials for effective treatments across the 8 major markets.

2024

Base Year

2018-2024

Historical Year

2025-2034

Forecast Year

  • Increased focus on clinical research for von Hippel-Lindau disease and expansion of treatment options targeting multiple manifestations of the condition is poised to impact the market growth.
  • The rising development of targeted therapies that offer better disease control and improved patient outcomes is a significant market trend.
  • Increasing healthcare spending, robust regulatory support for rare diseases, and the rise in research partnerships are expected to elevate the market value in the forecast period.

Von Hippel-Lindau Disease Market Overview

Von Hippel-Lindau disease or von Hippel-Lindau syndrome refers to a rare genetic disorder that causes the formation of tumors and fluid-filled sacs (cysts). The condition occurs due to a mutation in the VHL gene that codes for a protein regulating cell division. In von Hippel-Lindau disease patients, the faulty VHL protein can lead to uncontrolled cell growth and tumors. The rising advancements in targeted therapies and other treatment options that address multiple manifestations of the disease, including renal cell carcinoma and pheochromocytoma, are expected to support the market growth. Increased awareness about von Hippel-Lindau disease and the availability of genetic testing are further anticipated to boost the market demand. Moreover, the growing emphasis on multidisciplinary care approaches and combination therapies is likely to influence the market dynamics.

Von Hippel-Lindau Disease Market Growth Drivers

Rising Adoption of Targeted Therapies to Impact Market Growth

In October 2023, Scotland became the first European country to accept the use of Merck Sharp & Dohme’s Welireg (belzutifan), a hypoxia-inducible factor inhibitor, for eligible adult patients affected by von Hippel-Lindau (VHL) disease. Further, in September 2024, the National Health Service (NHS) England announced the availability of MSD’s belzutifan take-at-home oral pill for von Hippel-Lindau disease patients. The rising acceptance and adoption of targeted therapies that address the underlying genetic mutations causing the disease are expected to impact the market growth.

Von Hippel-Lindau Disease Market Trends

Von Hippel-Lindau Disease Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class:

  • Tyrosine Kinase Inhibitors (TKIs)
  • VEGF Inhibitors
  • HIF-2α Inhibitors
  • Immunotherapy
  • Others

Market Breakup by Tumor Site:

  • Brain
  • Spinal Cord
  • Eyes
  • Kidneys
  • Adrenal Glands
  • Pancreas
  • Liver
  • Lungs
  • Reproductive Tract
  • Others

Market Breakup by Route of Administration:

  • Oral
  • Parenteral
  • Others

Market Breakup by End User:

  • Hospitals & Specialty Clinics
  • Cancer Treatment Centers
  • Others

Market Breakup by Region:

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
  • United Kingdom
  • Japan
  • India

Von Hippel-Lindau Disease Market Share

The Tumor Site Segment Represents a Substantial Market Share

Based on the tumor site, the market is segmented into brain, spinal cord, eyes, kidneys, adrenal glands, pancreas, liver, lungs, reproductive tract and others. Kidneys are one of the most common and severe manifestations observed in von Hippel-Lindau disease patients. It poses as a serious cause of morbidity and mortality. The development of targeted therapies such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors for the management of von Hippel-Lindau disease-associated renal cell carcinoma is likely to support the growth of this segment. Further, the increasing prevalence of renal cell carcinoma and the rising adoption of precision medicine are likely to impact the market share of the segment in the coming years.

Von Hippel-Lindau Disease Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States leads the market for von Hippel-Lindau disease owing to its strong focus on oncology and rare disease research and the presence of major companies like Bristol Myers Squibb and Exelixis actively involved in drug development for the condition. The increase in the number of clinical trials and supportive regulatory frameworks for rare disease drugs are also anticipated to fuel the market growth. Moreover, the country's advanced healthcare infrastructure and collaborative research initiatives are poised to aid the market expansion in the forecast period.

Leading Players in the Von Hippel-Lindau Disease Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Merck & Co., Inc.

Headquartered in New Jersey, American multinational pharma Merck & Co. is one of the leading players in the market. In August 2021, Merck’s WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, received the approval of the U.S. Food and Drug Administration (FDA) to treat certain types of von Hippel-Lindau disease-associated tumors.

Bristol Myers Squibb Company

Bristol Myers Squibb, based in Princeton, New Jersey, was established in 1887 and is known for its f...

Novartis Pharmaceuticals

Swiss multinational pharmaceutical corporation Novartis Pharmaceuticals has a prominent presence in ...

Exelixis, Inc.

Exelixis, located in Alameda, California, is an oncology-based biotech company that is focused on pr...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Key Questions Answered in the Von Hippel-Lindau Disease Market Report

  • What was the von Hippel-Lindau disease market value in 2024?
  • What is the von Hippel-Lindau disease market forecast outlook for 2025-2034?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on drug class?
  • What is the market breakup based on tumor site?
  • What is the market breakup by route of administration?
  • Who are the major end users in the market?
  • What are the major factors aiding the von Hippel-Lindau disease market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How do the prevalence and incidence of von Hippel-Lindau disease affect the market landscape?
  • What are the major von Hippel-Lindau disease market trends?
  • How does the rising development of targeted therapies impact the market size?
  • Which drug class will dominate the market share?
  • Which tumor site is expected to have a high market value in the coming years?
  • Which route of administration will experience the highest demand in the market segment?
  • Which end user is projected to contribute to the highest market growth?
  • Who are the key players involved in the von Hippel-Lindau disease market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2024
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Tumor Site
  • Route of Administration
  • End User
  • Region
Breakup by Tumor Site
  • Brain
  • Spinal Cord
  • Eyes
  • Kidneys
  • Adrenal Glands
  • Pancreas
  • Liver
  • Lungs
  • Reproductive Tract
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by End User
  • Hospitals & Specialty Clinics
  • Cancer Treatment Centers
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Novartis Pharmaceuticals
  • Exelixis, Inc.

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,969

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124